Business Context and Reporting Period
This Form 8-K was filed by Halozyme Therapeutics, Inc. on March 8, 2011. The filing serves as a Regulation FD disclosure to update investor presentation materials originally furnished on January 10, 2011.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure regarding clinical trial updates and does not contain financial statements.
Material Changes and Updates
The company updated Slide 10 of its January 2011 investor presentation with the following specific developments:
- MabThera (rituximab): The subcutaneous formulation is confirmed to be in a Phase 3 clinical trial.
- Actemra: Identified as the third product candidate under Halozyme's existing partnership with F. Hoffmann-La Roche, Ltd and Hoffmann-La Roche, Inc.
- Actemra Status: Intravenously administered Actemra is approved for the treatment of rheumatoid arthritis.
Guidance, Outlook, and Risks
Management directs investors to page 2 of the January 2011 Presentation for a discussion of forward-looking statements and associated risks and uncertainties. The filing explicitly states that the information provided is not "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and will not be incorporated by reference into registration statements unless specifically identified.
Investor Verification Checklist
- Verify the Phase 3 clinical trial status of subcutaneous MabThera at clinicaltrials.gov and roche-trials.com.
- Review the full January 2011 Presentation (specifically page 2) for detailed risk factors and forward-looking statements.
- Confirm the scope of the partnership with F. Hoffmann-La Roche regarding Actemra development.